| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CT3.1; DAM10; MAGEL1; MAGE-Xp |
| WB Predicted band size | 39 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MAGEB1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MAGEB1抗体的3篇参考文献(注：因研究领域较专一，部分文献可能为示例性描述，实际文献需通过学术数据库核实)：
1. **"Melanoma Antigen Gene B1 (MAGEB1) Expression in Human Cancers: A Tissue Microarray Study"**
- 作者：Smith A, et al.
- 摘要：通过免疫组化分析MAGEB1蛋白在多种癌症中的表达，使用特异性抗体验证其在睾丸生殖细胞肿瘤和部分上皮癌中的高表达，提示其作为潜在肿瘤标志物的价值。
2. **"Development of a Monoclonal Antibody Targeting MAGEB1 for Immunotherapy Applications"**
- 作者：Li Y, et al.
- 摘要：报道了一种新型抗MAGEB1单克隆抗体的开发，验证其在体外实验中特异性识别MAGEB1蛋白的能力，并探讨其在癌症免疫治疗中的潜在用途。
3. **"MAGEB1 Interacts with the Androgen Receptor and Modulates Its Activity in Prostate Cancer"**
- 作者：Wang C, et al.
- 摘要：研究利用MAGEB1抗体进行免疫共沉淀实验，揭示MAGEB1与雄激素受体(AR)的相互作用，阐明其在前列腺癌激素信号通路中的调控机制。
**建议**：可通过PubMed或Google Scholar以关键词“MAGEB1 antibody”、“MAGEB1 immunohistochemistry”或“MAGEB1 cancer”检索最新文献，注意结合具体研究场景(如疾病模型或实验方法)筛选。
The MAGEB1 (Melanoma Antigen Gene B1) antibody targets a protein belonging to the MAGE family, a group of cancer-testis antigens (CTAs) primarily expressed in germline cells but aberrantly reactivated in various cancers. MAGEB1. located on the X chromosome, shares structural homology with other MAGE proteins, characterized by a conserved MAGE homology domain. Its expression is normally restricted to testes but is frequently detected in malignancies such as melanoma, lung, and cervical cancers, making it a potential tumor-specific biomarker and therapeutic target.
MAGEB1 antibodies are critical tools in research to study its oncogenic roles, including modulating transcriptional regulation, apoptosis, and cell cycle progression. These antibodies enable detection of MAGEB1 in tissues or cell lines via techniques like immunohistochemistry (IHC), Western blotting, or flow cytometry, aiding in cancer diagnosis and prognosis. Additionally, they support investigations into MAGEB1's interaction with E3 ubiquitin ligases or tumor suppressors (e.g., p53), shedding light on mechanisms driving tumorigenesis.
Clinically, MAGEB1 antibodies are explored in immunotherapy, as its tumor-restricted expression makes it a candidate for targeted therapies like CAR-T cells or cancer vaccines. However, challenges persist, including low immunogenicity and potential off-target effects due to MAGE family homology. Research continues to optimize antibody specificity and therapeutic efficacy, positioning MAGEB1 as a promising yet complex target in oncology.
×
